Abstract: A composite structural material and pharmaceutical composition comprising same, the use of the composite structural material in preparing a sustained release formulation, and a pharmaceutical composition formulation method; the composite structural material comprises a hydrophobic structural material and a hydrophilic structural material; the proportion of the hydrophobic structural material to the hydrophilic structural material ranges from 1:0.01 to 1:5, preferably 1:0.05 to 1:4, more preferably 1:0.1 to 1:3, and most preferably 1:0.4 to 1:2, such as 1:0.4 to 1:1.3. The pharmaceutical composition comprises the composite structural material and one or more active pharmaceutical ingredients, and preferably the proportion of the composite structural material to the active pharmaceutical ingredients ranges from 1:0.01 to 1:8, more preferably 1:0.02 to 1:5, and most preferably 1:0.03 to 1:1, such as 1:0.3 to 1:0.7.

Abstract: The present invention relates to a pharmaceutical composition comprising topiramate, and more particularly, to a solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients, wherein the weight ratio of topiramate to the cellulose derivative is 100:10 to 100. The pharmaceutical compositions of the present invention have excellent formulation properties as well. The pharmaceutical compositions of the present invention can be used for monotherapy for patients who are newly diagnosed with epilepsy, or patients who have been previously treated with combination therapy and now for monotherapy. They can also be used for the add-on treatment of partial seizures in adults and children aged 2 to 16 years.

Abstract: This invention provides a convenient process for preparing an oral contraceptive liquid formulation having improved solubility, bioavailability and stability useful as a reference standard.

Abstract: The invention relates to a substrate coating for the electrostatic deposition of dry powder medicaments for use in the manufacture of pharmaceutical dosage forms comprising micronized polyethylene glycol (PEG), with A molecular weight in the range of 1,000 to 20,000, and having a particle size of 1-100 &mgr;m. The invention also relates to pharmaceutical compositions having such a substrate coating, and processes for manufacturing such pharmaceutical compositions. The invention also relates to the technology of reversing negative charge of medicaments so that they can be electrostatically deposited on a negatively charged substrate.

Abstract: This invention provides a convenient process for preparing an oral contraceptive liquid formulation having improved solubility, bioavailability and stability useful as a reference standard.

Abstract: The invention relates to a substrate coating for the electrostatic deposition of dry powder medicaments for use in the manufacture of pharmaceutical dosage forms comprising micronized polyethylene glycol (PEG), with A molecular weight in the range of 1,000 to 20,000, and having a particle size of 1-100 &mgr;m. The invention also relates to pharmaceutical compositions having such a substrate coating, and processes for manufacturing such pharmaceutical compositions. The invention also relates to the technology of reversing negative charge of medicaments so that they can be electrostatically deposited on a negatively charged substrate.